Events

Safety Alert for Lentis Intraocular Lens

According to Food and Drug Administration Philippines, this safety alert involved a device in Philippines that was produced by Oculentis BV.

What is this?

Alerts provide important information and recommendations about products. Even though an alert has been issued, it does not necessarily mean a product is considered to be unsafe. Safety Alerts, addressed to health workers and users, may include recalls. They can be written by manufacturers, but also by health officials.

Learn more about the data here
  • Type of Event
    Safety alert
  • Event Number
    2017-288
  • Event Country
    Philippines
  • Event Source
    FDAP
  • Event Source URL
    https://ww2.fda.gov.ph//index.php/advisories-2/medical-devices-advisories-pertaining-to-all-regulated-medical-devices/471802-fda-advisory-no-2017-288
  • Notes / Alerts
    Data from the Philippines is current through 2019. All of the data comes from the Food and Drug Administration Philippines, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Philippines.
  • Extra notes in the data
  • Reason
    Fda advisory no. 2017-288 voluntary product recall of all lentis intraocular lens with expiry date between 2017-01 and 2020-05 all concerned healthcare professionals and establishments are hereby advised by the food and drug administration (fda) regarding the voluntary product recall of all lentis intraocular lens (iol) having an expiry date between 2017-01 and 2020-05 (see photos of the product below) distributed and imported by ophthaswissmed philippines inc. ophthaswissmed received a notice of product recall from the oculentis bv, the manufacturer of the above-mentioned medical device product. oculentis received notifications of sporadic late postoperative opacification of lentis iol’s. opacification may compromise the optical transparency of the iol’s in time, potentially leading to a slow reduction in the patient’s visual acuity. studies made by the manufacturer have indicated that opacification could possibly be the result of phosphate remnants from a phosphate-containing cleaning agent used in the production. oculentis assured that all currently produced and all lentis iol’s products on the market with an expiry date of 2020-06 or later are completely unaffected and may be used safely and effectively. all concerned healthcare professionals and establishments are advised to discontinue further use, sale and distribution of the said affected medical device product. for more information and inquiries, please email us at this email address is being protected from spambots. you need javascript enabled to view it. or call the product research and standards development division of the fda - center for device regulation, radiation health and research at 857-1900 local 8301. dissemination of the information to all concerned is requested.       attachments: fda advisory no. 2017-288.Pdf.

Device

Lentis Intraocular Lens

Manufacturer

Oculentis BV